419 related articles for article (PubMed ID: 28283856)
1. Effects of nintedanib on the microvascular architecture in a lung fibrosis model.
Ackermann M; Kim YO; Wagner WL; Schuppan D; Valenzuela CD; Mentzer SJ; Kreuz S; Stiller D; Wollin L; Konerding MA
Angiogenesis; 2017 Aug; 20(3):359-372. PubMed ID: 28283856
[TBL] [Abstract][Full Text] [Related]
2. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
[TBL] [Abstract][Full Text] [Related]
4. The Anti-fibrotic and Anti-inflammatory Potential of Bone Marrow-Derived Mesenchymal Stem Cells and Nintedanib in Bleomycin-Induced Lung Fibrosis in Rats.
Gad ES; Salama AAA; El-Shafie MF; Arafa HMM; Abdelsalam RM; Khattab M
Inflammation; 2020 Feb; 43(1):123-134. PubMed ID: 31646446
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib reduces ventilation-augmented bleomycin-induced epithelial-mesenchymal transition and lung fibrosis through suppression of the Src pathway.
Li LF; Kao KC; Liu YY; Lin CW; Chen NH; Lee CS; Wang CW; Yang CT
J Cell Mol Med; 2017 Nov; 21(11):2937-2949. PubMed ID: 28598023
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease.
Redente EF; Aguilar MA; Black BP; Edelman BL; Bahadur AN; Humphries SM; Lynch DA; Wollin L; Riches DWH
Am J Physiol Lung Cell Mol Physiol; 2018 Jun; 314(6):L998-L1009. PubMed ID: 29543042
[TBL] [Abstract][Full Text] [Related]
9. 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosis.
Gurrieri C; Piazza F; Gnoato M; Montini B; Biasutto L; Gattazzo C; Brunetta E; Cabrelle A; Cinetto F; Niero R; Facco M; Garbisa S; Calabrese F; Semenzato G; Agostini C
J Pharmacol Exp Ther; 2010 Mar; 332(3):785-94. PubMed ID: 19959748
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib reduces radiation-induced microscopic lung fibrosis but this cannot be monitored by CT imaging: A preclinical study with a high precision image-guided irradiator.
De Ruysscher D; Granton PV; Lieuwes NG; van Hoof S; Wollin L; Weynand B; Dingemans AM; Verhaegen F; Dubois L
Radiother Oncol; 2017 Sep; 124(3):482-487. PubMed ID: 28774597
[TBL] [Abstract][Full Text] [Related]
11. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
12. Lung function outcomes in the INPULSIS
Brown KK; Flaherty KR; Cottin V; Raghu G; Inoue Y; Azuma A; Huggins JT; Richeldi L; Stowasser S; Stansen W; Schlenker-Herceg R; Maher TM; Wells AU
Respir Med; 2019 Jan; 146():42-48. PubMed ID: 30665517
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal x-ray based lung function measurement for monitoring Nintedanib treatment response in a mouse model of lung fibrosis.
Khan A; Markus MA; Svetlove A; Hülsmann S; Alves F; Dullin C
Sci Rep; 2023 Oct; 13(1):18637. PubMed ID: 37903864
[TBL] [Abstract][Full Text] [Related]
14. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
[TBL] [Abstract][Full Text] [Related]
15. Improvement of the pharmacokinetics and antifibrotic effects of nintedanib by intrapulmonary administration of a nintedanib-hydroxypropyl-γ-cyclodextrin inclusion complex in mice with bleomycin-induced pulmonary fibrosis.
Togami K; Ogasawara A; Irie S; Iwata K; Yamaguchi K; Tada H; Chono S
Eur J Pharm Biopharm; 2022 Mar; 172():203-212. PubMed ID: 35183716
[TBL] [Abstract][Full Text] [Related]
16. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity.
Sato S; Shinohara S; Hayashi S; Morizumi S; Abe S; Okazaki H; Chen Y; Goto H; Aono Y; Ogawa H; Koyama K; Nishimura H; Kawano H; Toyoda Y; Uehara H; Nishioka Y
Respir Res; 2017 Sep; 18(1):172. PubMed ID: 28915889
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib Reduces Neutrophil Chemotaxis via Activating GRK2 in Bleomycin-Induced Pulmonary Fibrosis.
Chen WC; Chen NJ; Chen HP; Yu WK; Su VY; Chen H; Wu HH; Yang KY
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32630825
[TBL] [Abstract][Full Text] [Related]
18. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
[TBL] [Abstract][Full Text] [Related]
19. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
20. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
